KASMEJ
Kastamonu Medical Journal

Kastamonu Medical Journal regularly publishes internationally qualified issues in the field of Medicine in the light of up-to-date information.

eISSN: 2757-9336
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
An investigation of the association between lipoxin A4 levels and metabolic syndrome parameters in patients with metabolic syndrome
Abstract
Aim: Metabolic syndrome (MS) is a significant public health problem and has the potential to increase the risk of developing cardiovascular diseases (CVD), the risk of type 2 Diabetes Mellitus (T2DM), the risk of stroke and the risk of a heart attack. MS has recently been considered an inflammatory disease. Lipoxins (LXs) are, on the other hand, bioactive lipid molecules synthesized from arachidonic acid (AA) and show potent anti-inflammatory and pro-resolving activities in vivo and in vitro conditions. In this study, we aimed to evaluate serum levels of LXA4 in MS patients and explore the relationship of serum LXA4 levels with MS components [waist circumference, blood pressure, serum high-density lipoprotein (HDL), and triglyceride (TG) levels]. Material and Method: In this study, the sample was composed of 39 patients diagnosed with MS and 32 healthy age- and sex-matched individuals. We measured serum LXA4 levels adopting the enzyme-linked immunosorbent assay (ELISA) method with “Human Lipoxin A4 ELISA Kit”. While collecting the blood samples from the subjects, we noted their ages, sex, physical examination findings, and anthropometric measurements [height, weight, waist circumference, and body mass index (BMI)]. Additionally, we obtained their serum TG, low-density lipoprotein (LDL), HDL, glucose, and cholesterol levels. Results: While we could not find any significant differences between the groups by age and sex (p>0.05), the groups significantly differed by weight, waist circumference, BMI, systolic blood pressure, diastolic blood pressure, TG, HDL, and FBG (p<0.05 for TG; p<0.001 for others). Moreover, serum levels of LXA4 significantly differed between the groups (p<0.05). Within-group comparisons showed that while serum levels of LXA4 significantly differed between male subjects (p=0.01), it was not the case for females (p>0.05). In both groups, there were negative correlations between serum LXA4 levels and waist circumference (r=-0.368 p=0.02). Yet, we found such an association only among male patients (r=-0.516 p=0.02). Conclusion: Overall, we found serum LXA4 levels to be significantly low in MS patients (p<0.05). Yet, it still needs to be elucidated whether this impairment is a cause or a result of MS. Finally, we discovered this impairment and its significant correlations with some MS parameters to be only in male patients, suggesting that serum LXA4 levels may vary by sex in MS patients.

Keywords : Lipoxin A4, metabolic syndrome, metabolic syndrome parameters

Download Article


1. Jaspinder Kaur. &ldquo;A Comprehensive review on metabolic syndrome&rdquo;. Cardiology Research and Practice. 2014. vol. 2014. pp 1-21.
2. K. G. M. M. Alberti. R. H. Eckel. S. M. Grundy et al.. &ldquo;Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart. lung. and blood institute; American heart association; World heart federation; International atherosclerosis society; and lnternational association for the study of obesity.&rdquo; Circulation. 2009. vol. 120. no. 16. pp. 1640-1645.
3. K. G.M.M. Alberti andP. Zimmet. &ldquo;The metabolic syndrome. a new worldwide definition.&rdquo; The Lancet. 2005. vol. 366. no. 9491. pp. 1059-1062.
4. S. M. Grundy. &ldquo;Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds.&rdquo; Journal of the AmericanCollege of Cardiology. 2006. vol. 47. no. 6. pp. 1093-1100.
5. G. S. Hotamisligil. &ldquo;Inflammation and metabolic disorders.&rdquo; Nature. 2006. vol. 444. no. 7121. pp. 860-867.
6. R. Medzhitov. &ldquo;Origin and physiological roles of inflammation.&rdquo; Nature. 2008. vol. 454. no. 7203. pp. 428-435.
7. R. Monteiro. &ldquo;Chronic inflammation in the metabolic syndrome: emphasis on adipose tissue.&rdquo; in Oxidative Stress.Inflammation and Angiogenesis in the Metabolic Syndrome. R. Soares and C. Costa.Eds.. 2009. pp. 65-83. Springer Science.NewYork. NY. USA.
8. Mario Romano. Irene Recchia. and Antonio Recchiuti. &ldquo;Lipoxin Receptors Eicosanoid Receptors and Inflammation&rdquo; The Scientific World Journal.2007.no.7. pp 1393-1412.
9. Fiore. S. and Serhan. C.N. &ldquo;Formation of lipoxins and leukotrienes during receptor-mediated interactions of human platelets and recombinant human granulocyte/macrophage colony-stimulating factor-primed neutrophils. J. Exp. Med. 1990. no.172. pp 1451-1457.
10. Serhan CN. &ldquo;Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): a jungle of cell-cell interactions or a therapeutic opportunity?&rdquo; Prostaglandins. 1997. no. 53. pp 107-137.
11. Serhan C.N. &ldquo;Systems approach to inflammation resolution: identification of novel anti-inflammatory and pre-resolving mediators.&rdquo; J. Thromb.Haemost..2009. 7 (Suppl.1). pp 44-48.
12. AritaM.. Yoshida M.. Hong S..TjonahenE.. Glickman.J.N..Petasis.N.A.. et al. &ldquo;Resolvin E1. an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid. protects against 2.4.6-trinitrobenzene sulfonic acid- induced colitis. Proc.Natl.Acad.Sci. U.S.A..2005.vol.102. pp 7671-7676.
13. Serhan C.N..Yacoubian.S. And Yang. R. &ldquo;Anti-inflammatory and proresolving lipid mediators.&rdquo; Annu. Rev.Pathol. 2008.vol 3. pp 279-312.
14. Maderna P. and Godson C.. &ldquo;Lipoxins: resolution a ryroad. Br.J. Pharmacol. 2009. vol.158. pp 947-959.
15. International Diabetes Federation: The IDF consensus worldwide definition of the metabolic syndrome.<a href="http://www.idf.org/metabolic-syndrome">http://www.idf.org/metabolic-syndrome</a>.
16. Levy. B. D. et al. &ldquo;Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness.&rdquo; J. Immunol. 2007.178. 496-502.
17. Karp. C. L. et al. &ldquo;Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway.&rdquo; Nature Immunol..2004.5. 388-392.
18. Zhangye Xu.M.D.. Feng Zhao.M.M.. Feng Lin.M.M..&rdquo; Preeclampsia is associated with a deficiency of lipoxin A4. an endogenous anti-inflammatory mediator.&rdquo; Fertility and Sterility. 2014.
19. Feuerstein G. Siren AL. &ldquo;Mesenteric vascular responses to i.v. administration of lipoxin A4 and lipoxin B4 in the conscious rat.&rdquo; FEBS Lett.. 1988;232:51-55.
20. SuX.. Feng X..Terrando N. &ldquo;Dysfunction of Inflammation-Resolving Pathways Is Associated with Exaggerated Postoperative Cognitive Decline in a Rat Model of the Metabolic Syndrome&rdquo; MOL MED. 2012. 18 : 1481 - 1490.
21. TitosE..Cl&agrave;ria J. &ldquo;Omega-3-derived mediators counteract obesity-induced adiposetissue inflammation.&rdquo; Prostaglandins and Other Lipid Mediators. 2013. http://dx.doi.org/10.1016/j.prostaglandins.2013.05.003
22. Titos E.Rius B. Gonz&aacute;lez-P&eacute;riz A. et al. &ldquo;Resolvin D1 and its precursordocosahexaenoic acid promote resolution of adipose tissue inflammation byeliciting macrophage polarization toward an M2-like phenotype.&rdquo; J Immunol 2011;15:5408-18.
23. Gonz&aacute;lez-P&eacute;riz A.Horrillo R.Ferr&eacute; N. et al. &ldquo;Obesity-induced insulin resistanceand hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvinsandprotectins.&rdquo; FASEB J. 2009; 23: 1946-57.
24. Neuhofer A.Zeyda M.Mascher D. et al. &ldquo;Impaired local productionof pre-resolving lipid mediators in obesity and 17-HDHA as a poten-tial treatment for obesity-associated inflammation.&rdquo; Diabetes 2013;January.http://dx.doi.org/10.2337/db12-0828.
25. Mauro CR. Lonzo G. Nguyen BT. et al. &ldquo;Attenuated adiposopathy in perivascularadipose tissue compared with subcutaneous human adipose tissue.&rdquo; Am J Surg 2013;January.<a href="http://dx.doi.org/10.1016/j.amjsurg.2012.07.032">http://dx.doi.org/10.1016/j.amjsurg.2012.07.032</a>.
26. Lin F.. Zeng P.. Xu Z. &ldquo;Treatment of Lipoxin A4 and its analogue on low-dose endotoxin induced preeclampsia in rat and possible mechanisms.&rdquo; Reproductive Toxicology. 2012. 34. 677- 685.
27. SobradoM.. Pereira M. P..1 Ballesteros I.. &ldquo;Synthesis of Lipoxin A4 by 5-Lipoxygenase Mediates PPAR&gamma;- Dependent. Neuroprotective Effects of Rosiglitazone in Experimental Stroke.&rdquo; The Journal of Neuroscience. March 25. 2009 29(12): 3875-3884.
28. Yu D.Xu Z.Yin X.Zheng F. Lin X.Pan Q. et al. InverseRelationshipbetween Serum Lipoxin A4 Level andthe Risk of MetabolicSyndrome in a Middle-Aged Chinese Population. PLoSOne 2015;10:e0142848.
29. Kim OS.Shin MH.Kweon SS. Lee YH. Kim OJ. Kim YJ.et al. Theseverity of periodontitis and metabolic syndrome in Koreanpopulation: theDong-gustudy. J PeriodontalRes 2018;53:362-8.
30. Doğan ESK. Doğan B.Fentoğlu &Ouml;.Kırzıoğlu FY. The role of serum lipoxin A4 levels in theassociationbetweenperiodontaldiseaseandmetabolicsyndrome. J PeriodontalImplantSci. 2019 Apr 24;49(2):105-113. doi: 10.5051/jpis.2019.49.2.105. PMID: 31098331; PMCID: PMC6494773.
Article available in :
Volume 1, Issue 4, 2021
Page : 105-109
https://doi.org/10.51271/KMJ-0023
Article Information
Received : 19 Eki 2021
Accepted : 30 Kas 2021
Published : 29 Ara 2022
Corresponding Author :

Sedat Gülten: Department of Medical Biochemistry, Faculty of Medicine, Kastamonu University, Kastamonu, Turkiye

[email protected]
Citation : Gülten S, Akçay F. An investigation of the association between lipoxin a4 levels and metabolic syndrome parameters in patients with metabolic syndrome. Kastamonu Med J. 2021;1(4): 105-109.

Read: 198
Cited: 0
Download : 273
_Footer